Synthesis of Novel 1,4- Dihydropyridine Derivatives Bearing Biphenyl-2'-Tetrazole Substitution as Potential Dual Angiotensin II Receptors and Calcium Channel Blockers

Introduction: We report the synthesis of novel 1,4-dihydropyridine derivatives containing biphenyl-2'-tetrazole moieties. We hypothesized that merging the key structural elements present in an AT1 receptor antagonist with key structural elements in 1,4-dihydropyridine calcium channel blockers w...

Full description

Bibliographic Details
Published in:	Advanced Pharmaceutical Bulletin
Main Authors:	Javid Shahbazi Mojarrad, Zahra Zamani, Hossein Nazemiyeh, Saeed Ghasemi, Davoud Asgari
Format:	Article
Language:	English
Published:	Tabriz University of Medical Sciences 2011-06-01
Subjects:	1 4-Dihydropyridine Biphenyl-2'-tetrazole Angiotensin II Blocker Calcium Channel blocker
Online Access:	http://apb.tbzmed.ac.ir/Portals/0/Archive/Vol1No1/1-asgari.pdf

Similar Items

Combined use of beta-blockers and non-dihydropyridine calcium channel blockers: possible or contraindicated?
by: S. S. Yakushin, et al.
Published: (2024-02-01)

Vasorelaxant Effect of a Newly Synthesized Dihydropyridine Ethyl Ester (DHPEE) on Rat Thoracic Aorta: Dual Mechanism of Action
by: Hossein Babaei, et al.
Published: (2011-06-01)

Design and synthesis of novel 4-substituted 1,4-dihydropyridine derivatives as hypotensive agents
by: Prasanna A. Datar, et al.
Published: (2016-09-01)

Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers
by: K. Makarounas-Kirchmann, et al.
Published: (2010-12-01)

The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
by: Tao Liu, et al.
Published: (2023-01-01)

Molecular targeting therapy with angiotensin II receptor blocker for prostatic cancer
by: Hiroji Uemura, et al.
Published: (2011-12-01)

Effects of Angiotensin Receptor Blockers on Apelin and Visfatin in Hypertension
by: Mina Mohammed, et al.
Published: (2024-06-01)

Reappraisal of role of angiotensin receptor blockers in cardiovascular protection
by: Ram CV
Published: (2011-05-01)

Angiotensin receptor blocker-induced bilateral ciliochoroidal effusion
by: Kanika Aggarwal, et al.
Published: (2020-01-01)

Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers
by: Di Zhang, et al.
Published: (2021-11-01)

Is there a difference between an angiotensin-converting enzyme inhibitor and an angiotensin-specific receptor blocker for the treatment of hypertension?
by: James A. Ker
Published: (2015-05-01)

Prolonged Postoperative Vasoplegia in Pediatric Patients on Chronic Angiotensin II Blocker Treatment
by: Nischal R. Pandya, et al.
Published: (2018-09-01)

Effect of angiotensin-converting enzyme inhibitors versus that of angiotensin receptor blockers on survival in patients undergoing hemodialysis: a nationwide observational cohort study
by: Seok Hui Kang, et al.
Published: (2024-12-01)

The Evolving Role of Calcium Channel Blockers in Hypertension Management: Pharmacological and Clinical Considerations
by: Kamryn E. Jones, et al.
Published: (2024-06-01)

Nephroprotective effect of vitamin E added to angiotensin receptor blocker in patients with diabetic nephropathy
by: Abdulrazzaq Alkaaby, et al.
Published: (2021-12-01)

Association of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID‐19
by: Rohan Khera, et al.
Published: (2021-07-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Hyperkalemia Associated with Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blockers in Chronic Kidney Disease
by: Yudi Her Oktaviono, et al.
Published: (2020-04-01)

Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers-A Pilot Study
by: S Bhuvaneshwari, et al.
Published: (2018-07-01)

ANGIOTENSIN RECEPTOR BLOCKERS WITH PLEIOTROPIC PROPERTIES: A NEW STANDARD IN CARDIOVASCULAR RISK MANAGEMENT AND TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2017-07-01)

Rationale and Design of a Randomized, Open‐Label, Parallel‐Group Study of Esaxerenone Versus Angiotensin Receptor Blockers in Older Patients With Uncontrolled Hypertension on Calcium Channel Blocker Monotherapy (ESCORT‐HT)
by: Kazuomi Kario, et al.
Published: (2025-01-01)

A study of prognosis and outcome of COVID-19-infected hypertensive patients on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
by: M S Bharath, et al.
Published: (2024-01-01)

Kynurenine/Tryptophan Ratio Predicts Angiotensin Receptor Blocker Responsiveness in Patients with Diabetic Kidney Disease
by: Ming-Hsien Wu, et al.
Published: (2020-04-01)

Angiotensin II receptor blockers as a risk factor for skin ulcers
by: Raúl Gonzalez-Fregoso, et al.
Published: (2021-10-01)

Efficacy of angiotensin receptor blockers for erectile dysfunction in hypertensive men: A systematic review
by: Swati Sucharita Dash, et al.
Published: (2024-01-01)

POSSIBILITY OF ANGIOTENSIN RECEPTOR BLOCKERS IN OPTIMIZING OF ANTIHYPERTENSIVE PHARMACOTHERAPY IN PATIENTS AFTER STROK
by: Z M. Sizova
Published: (2015-09-01)

Real-world efficacy of fimasartan vs. other angiotensin receptor blockers in combination with calcium channel blockers: a nationwide cohort study
by: Huijin Lee, et al.
Published: (2024-10-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

Prospective direct comparison of antihypertensive effect and safety between high-dose amlodipine or indapamide in hypertensive patients uncontrolled by standard doses of angiotensin receptor blockers and amlodipine
by: Keisuke Okamura, et al.
Published: (2018-02-01)

Use of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Is Associated With a Reduced Risk of Poststroke Epilepsy in Patients With Ischemic Stroke
by: Kuo‐Cheng Chang, et al.
Published: (2024-09-01)

Blocking angiotensin earlier with RAS blockers, statins, and heparin in high-risk COVID-19 patients: Is the remedy here?
by: Imdat Eroğlu, et al.
Published: (2020-07-01)

Impact of Angiotensin Receptor Blockers Use on In-Hospital Mortality in Community-Acquired Pneumonia Patients with Hypertension
by: Dawei Chen, et al.
Published: (2023-06-01)

Evaluation of drug promotional literatures on angiotensin receptor blockers using World Health Organization criteria
by: Debasree Bhaumik, et al.
Published: (2022-11-01)

Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Contrast-Induced Nephropathy
by: Letian Zhou, et al.
Published: (2014-03-01)

Angiotensin‐Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID‐19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System
by: Jaejin An, et al.
Published: (2021-02-01)

Preventative Effect of Angiotensin Receptor Blockers on Moderate-to-Severe Cerebral Vasospasm Among Patients Who Received Interventions for Aneurysmal Subarachnoid Hemorrhage
by: Si Un Lee, et al.
Published: (2025-02-01)

Effectiveness of angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers on total and cardiovascular mortality and morbidity in primary prevention: A nationwide study based on French Health Insurance Data (SNDS)
by: Emmanuel Oger, et al.
Published: (2022-04-01)

A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors
by: Siragy H
Published: (2011-05-01)

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers impact on the gut microbiome: a systematic review
by: Elisabeth M. Wang, et al.
Published: (2025-10-01)

Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all‐cause mortality and other clinical outcomes in patients with confirmed COVID‐19: A systemic review and meta‐analysis
by: Na Jia, et al.
Published: (2021-09-01)